{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T11:04:50Z","timestamp":1788865490533,"version":"build-2803163510"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2017,9,27]],"date-time":"2017-09-27T00:00:00Z","timestamp":1506470400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["17K08452"],"award-info":[{"award-number":["17K08452"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0185654","type":"journal-article","created":{"date-parts":[[2017,9,27]],"date-time":"2017-09-27T13:46:38Z","timestamp":1506519998000},"page":"e0185654","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":64,"title":["Comparison of the adverse event profiles of conventional and liposomal formulations of doxorubicin using the FDA adverse event reporting system"],"prefix":"10.1371","volume":"12","author":[{"given":"Akiho","family":"Fukuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohei","family":"Tahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuuki","family":"Hane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshinobu","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayaka","family":"Sasaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruna","family":"Hatahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Motooka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Misa","family":"Naganuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5062-5522","authenticated-orcid":true,"given":"Mitsuhiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,9,27]]},"reference":[{"key":"ref1","unstructured":"Company P&amp; U. Doxorubicin Hydrochloride for Injection, USP; 2010. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/050467s070lbl.pdf\" xlink:type=\"simple\">https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/050467s070lbl.pdf<\/ext-link>"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/IJN.S26766","article-title":"Clinical development of liposome based drugs: formulation, characterization, and therapeutic efficacy","volume":"7","author":"M-K Yeh","year":"2011","journal-title":"Int J Nanomedicine"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1200\/JCO.1997.15.3.987","article-title":"Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation","volume":"15","author":"FM Muggia","year":"1997","journal-title":"J Clin Oncol"},{"issue":"7","key":"ref4","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0959-8049(01)00050-8","article-title":"Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL\/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group","volume":"37","author":"I Judson","year":"2001","journal-title":"Eur J Cancer"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3892\/ol.2016.4740","article-title":"Non-pegylated liposomal doxorubicin for patients with recurrent ovarian cancer: A multicentric phase II trial","volume":"12","author":"J Brucker","year":"2016","journal-title":"Oncol Lett"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S0076-6879(05)91004-5","article-title":"The liposomal formulation of doxorubicin","volume":"391","author":"SA Abraham","year":"2005","journal-title":"Methods Enzymol"},{"issue":"7","key":"ref7","doi-asserted-by":"crossref","DOI":"10.3390\/nano6070125","article-title":"Soft interaction in liposome nanocarriers for therapeutic drug delivery","volume":"6","author":"D Lombardo","year":"2016","journal-title":"Nanomaterials (Basel)"},{"issue":"6","key":"ref8","doi-asserted-by":"crossref","first-page":"5332","DOI":"10.3892\/ol.2016.5309","article-title":"Skin toxicity in a patient with ovarian cancer treated with pegylated liposomal doxorubicin: A case report and review of the literature","volume":"12","author":"J Kubicka-Wo\u0142kowska","year":"2016","journal-title":"Oncol Lett"},{"issue":"7","key":"ref9","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/annonc\/mdl477","article-title":"Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (\u2018hand-foot\u2019 syndrome)","volume":"18","author":"D Lorusso","year":"2007","journal-title":"Ann Oncol"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"EP van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"ref11","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data Mining of the Public Version of the FDA Adverse Event Reporting System","volume":"10","author":"T Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"issue":"5","key":"ref12","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1248\/bpb.b14-00191","article-title":"Analysis of the Interaction between Clopidogrel, Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System Database","volume":"38","author":"Y Suzuki","year":"2015","journal-title":"Biol Pharm Bull"},{"issue":"10","key":"ref13","doi-asserted-by":"crossref","first-page":"e0164309","DOI":"10.1371\/journal.pone.0164309","article-title":"Time-to-Onset Analysis of Drug-Induced Long QT Syndrome Based on a Spontaneous Reporting System for Adverse Drug Events","volume":"11","author":"S Sasaoka","year":"2016","journal-title":"PLoS One"},{"issue":"4","key":"ref14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.7150\/ijms.10703","article-title":"Evaluation of dabigatran- and warfarin-associated hemorrhagic events using the FDA-adverse event reporting system database stratified by age","volume":"12","author":"J Abe","year":"2015","journal-title":"Int J Med Sci"},{"issue":"11","key":"ref15","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1248\/bpb.b15-00243","article-title":"Association between Selective Serotonin Reuptake Inhibitor Therapy and Suicidality: Analysis of U.S. Food and Drug Administration Adverse Event Reporting System Data","volume":"38","author":"R Umetsu","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1248\/bpb.b15-00253","article-title":"Analysis of neuropsychiatric adverse events in patients treated with oseltamivir in spontaneous adverse event reports","volume":"38","author":"N Ueda","year":"2015","journal-title":"Biol Pharm Bull"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40780-015-0015-6","article-title":"Hyperglycemic adverse events following antipsychotic drug administration in spontaneous adverse event reports","volume":"1","author":"Y Kato","year":"2015","journal-title":"J Pharm Health Care Sci"},{"issue":"6","key":"ref18","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting","volume":"18","author":"A Bate","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"MER O\u2019Brien","year":"2004","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"7","key":"ref20","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1093\/annonc\/mdi204","article-title":"Release of doxorubicin in sweat: first step to induce the palmar-plantar erythrodysesthesia syndrome?","volume":"16","author":"U Jacobi","year":"2005","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"6","key":"ref21","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.breast.2010.05.008","article-title":"Non-pegylated liposomal doxorubicin in metastatic breast cancer patients: a valuable therapeutic option requiring caution","volume":"19","author":"D Bernardi","year":"2010","journal-title":"Breast"},{"issue":"2","key":"ref22","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/1078155215621150","article-title":"Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS)","volume":"23","author":"S Wittayanukorn","year":"2017","journal-title":"J Oncol Pharm Pract"},{"issue":"12 Suppl No 14","key":"ref23","first-page":"31","article-title":"Effect of celecoxib on capecitabine-induced hand-foot syndrome and antitumor activity","volume":"16","author":"E Lin","year":"2002","journal-title":"Oncology (Williston Park)"},{"issue":"1\u20132","key":"ref24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0168-3659(99)00248-5","article-title":"Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review","volume":"65","author":"H Maeda","year":"2000","journal-title":"J Control Release"},{"issue":"11","key":"ref25","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0145-2126(03)00092-4","article-title":"OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL","volume":"27","author":"B Tomkinson","year":"2003","journal-title":"Leuk Res"},{"issue":"5","key":"ref26","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","article-title":"Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma","volume":"89","author":"O Lyass","year":"2000","journal-title":"Cancer"},{"issue":"10","key":"ref27","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.1997.15.10.3185","article-title":"Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial","volume":"15","author":"MR Ranson","year":"1997","journal-title":"J Clin Oncol"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ygyno.2016.02.033","article-title":"Equivalency challenge: Evaluation of Lipodox<sup>\u00ae<\/sup> as the generic equivalent for Doxil<sup>\u00ae<\/sup> in a human ovarian cancer orthotropic mouse model","volume":"141","author":"JA Smith","year":"2016","journal-title":"Gynecol Oncol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jconrel.2016.05.010","article-title":"Exploring the relationship between anti-PEG IgM behaviors and PEGylated nanoparticles and its significance for accelerated blood clearance","volume":"234","author":"K Shiraishi","year":"2016","journal-title":"J Control Release"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1248\/yakushi.128.233","article-title":"Accelerated blood clearance (ABC) phenomenon induced by administration of PEGylated liposome","volume":"128","author":"T Ishida","year":"2008","journal-title":"Yakugaku Zasshi"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.jconrel.2007.02.010","article-title":"Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes","volume":"119","author":"X Wang","year":"2007","journal-title":"J Control Release"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/2162-3619-1-10","article-title":"Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis","volume":"1","author":"SM Rafiyath","year":"2012","journal-title":"Exp Hematol Oncol"},{"issue":"25","key":"ref33","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJM200006223422507","article-title":"Randomized, controlled trials, observational studies, and the hierarchy of research designs","volume":"342","author":"J Concato","year":"2000","journal-title":"New Engl J Med"},{"issue":"1","key":"ref34","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1365-2125.2008.03176.x","article-title":"A signal of increased risk of hypoglycaemia with angiotensin receptor blockers caused by confounding","volume":"66","author":"F Gr\u00e9goire","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"ref35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","article-title":"Novel statistical tools for monitoring the safety of marketed drugs","volume":"82","author":"JS Almenoff","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"ref36","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00592-011-0340-7","article-title":"The association of pancreatitis with antidiabetic drug use: gaining insight through the FDA pharmacovigilance database","volume":"50","author":"E Raschi","year":"2013","journal-title":"Acta Diabetol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0185654","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T21:20:03Z","timestamp":1570137603000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0185654"}},"subtitle":[],"editor":[{"given":"Han-Chung","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,9,27]]},"references-count":36,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9,27]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0185654","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,27]]}}}